Career Development Program
Career Development Program
批准号:
8932167
负责人:
KEVIN M. SHANNON
金额:
$10.45万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-01 至 2020-08-31
关键词:
AddressAreaBasic ScienceBudgetsCaliforniaCancer BiologyChildhoodCitiesClinicalClinical SciencesDataDevelopmentDevelopment PlansDisadvantagedDisciplineExtramural ActivitiesFacultyFundingGoalsHumanIndianaIndividualInstitutionKnowledgeLesbian Gay BisexualLinkMalignant NeoplasmsMedical centerMentorsMissionMutationNF1 geneNational Cancer InstituteNatureNorth CarolinaPediatric HospitalsPennsylvaniaPhiladelphiaPopulationProcessRecruitment ActivityReproduction sporesResearchResearch PersonnelResearch Project GrantsResourcesSan FranciscoScheduleScientistSignal TransductionStructureTexasTextilesTherapeuticTrainingTranslational ResearchUnderrepresented MinorityUniversitiesWomanWorkabstractinganticancer researchcancer therapycareercareer developmentethnic minority populationinnovationmeetingsmemberprofessorprogramsskillssuccesstransgendertumor
中文摘要
抽象--职业发展计划
发展性高活动性RAS肿瘤(DHART)孢子职业发展计划(CDP)将
支持助理教授级别的教员从事以NF1和癌症为重点的翻译研究。
CDP的具体目的是促进正在发展中的初级调查员的职业生涯
与实施更有效和毒性更低的治疗方法的目标有关的创新研究项目
以NF1突变为特征的癌症。达特孢子还包括一项发展研究
计划(DRP),该计划的补充任务是为寻求
开发与NF1相关癌症相关的新研究,并在本申请的单独部分中介绍。
这个孢子的多机构性质利用了一大批有才华的初级教员
纪律。每个机构都将CDP视为招募、培训和提升年轻科学家的工具
从事与NF1相关的转化型癌症研究,他们已承诺提供130万美元
支持DHART孢子发展计划部分(DRP和CDP)。具体目标
CDP的目标是:(1)支持新的研究人员开发创新的研究计划,目标是
为NF1相关癌症研究领域贡献新知识,同时生成初步数据,
将使他们能够成功地申请独立的校外资金;(2)为青年研究人员提供
教育培训,将使他们具备作为独立人士取得成功所需的基本技能和知识
NF1相关癌症研究领域的研究员;(3)通过以下方式指导年轻的翻译研究人员
定期安排与指定的高级教员和有条理的个人举行一对一会议
职业发展计划(IDP),将CDP支持的调查员完全纳入
在那里他们可以获得建议、资源和潜在的合作者;以及,(4)
鼓励招募少数族裔、弱势群体、妇女和
将女同性恋者/男同性恋者/双性恋者/变性者(LGBT)人群纳入重点研究NF1相关癌症的研究。这个
DHART孢子将与所有联盟机构的多样性计划进行垂直和水平的链接。
来自这些中心的调查人员可以申请CDP资金,我们也将考虑来自
其他机构的研究人员。CDP将每年至少资助两个项目,年度预算为
5万-7.5万美元。CDP支持的申请(包括第二年的资助申请)将是
通过竞争性过程进行评估,并由发展计划指导委员会进行审查
由参与该孢子的敏感科学家组成,并来自外部和
内部顾问委员会。
英文摘要
ABSTRACT – CAREER DEVELOPMENT PROGRAM
The Developmental Hyperactive Ras Tumor (DHART) SPORE Career Development Program (CDP) will
support faculty at the Assistant Professor level to engage in translational research focused on NF1 and cancer.
The specific purpose or the CDP is to advance the careers of junior investigators who are developing
innovative research projects related to the goal of implementing more effective and less toxic therapies for
cancers characterized by NF1 mutations. The DHART SPORE also includes a Developmental Research
Program (DRP), which has the complementary mission of funding established investigators who seek to
develop new research related to NF1-related cancers and is presented in a separate section of this application.
The multi-institutional nature of this SPORE leverages a large and talented pool of junior faculty from multiple
disciplines. Each institution views the CDP as a vehicle for recruiting, training, and advancing young scientists
working in the area of translational cancer research related to NF1, and they have committed $1.3 million to
support the Developmental Programs component of the DHART SPORE (DRP and CDP). The Specific Aims
of the CDP are: (1) to support new investigators as they develop innovative research programs with the goal of
contributing new knowledge to the field of NF1-related cancer research while generating preliminary data that
will allow them to successfully apply for independent extramural funding; (2) to provide young researchers with
didactic training that will equip them with essential skills and knowledge for success as an independent
investigator in the field of NF1-related cancer research; (3) to mentor young translational researchers through
regularly scheduled one-on-one meetings with a designated senior faculty member and a structured Individual
Career Development Plan (IDP) who will fully integrate the CDP-supported investigator into the fabric of the
DHART SPORE where they have access to advice, resources, and potential collaborators; and, (4) to
encourage the recruitment of ethnic minorities, those from disadvantaged backgrounds, women and
lesbian/gay/bisexual/transgender (LGBT) populations into research focused on NF1-associated cancers. The
DHART SPORE will link vertically and horizontally to diversity programs at all of the consortium institutions.
Investigators from any of these centers can apply for CDP funds, and we will also consider proposals from
researchers at other institutions. The CDP will fund a minimum of two projects per year at an annual budget of
$50,000 - $75,000. Applications for CDP support (including requests for a second year of funding) will be
evaluated through a competitive process with review by a Developmental Programs Steering Committee
comprised on senor scientists participating in this SPORE and oversight and guidance from the External and
Internal Advisory Boards.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In Vivo Functional Analysis of Chromosome 7q22 Deletions in Myeloid Malignancies
-
批准号:9924474
-
项目类别:
-
资助金额:$33.87万
-
财政年份:2017
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:10372214
-
项目类别:
-
资助金额:$50.61万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Project 3: Efficacy of MEK Inhibition in Juvenile Myelomonocytic Leukemia
-
批准号:8932164
-
项目类别:
-
资助金额:$43.13万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:10209682
-
项目类别:
-
资助金额:$53.18万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Developmental Research Program
-
批准号:8932166
-
项目类别:
-
资助金额:$10.45万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:9040123
-
项目类别:
-
资助金额:$55.05万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:10610346
-
项目类别:
-
资助金额:$50.61万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Career Enhancement Program
-
批准号:10494113
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Developmental Research Program
-
批准号:10494111
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
PROJECT 3: A High Content Clinical Trial of the MEK inhibitor Trametinib in JMML
-
批准号:10270583
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
PROJECT 3: A High Content Clinical Trial of the MEK inhibitor Trametinib in JMML
-
批准号:10494109
-
项目类别:
-
资助金额:$37.55万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Selectively Targeting Oncogenic NRAS in Cancer
-
批准号:9278130
-
项目类别:
-
资助金额:$49.7万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Developmental Research Program
-
批准号:10270584
-
项目类别:
-
资助金额:$9.02万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
Career Enhancement Program
-
批准号:10270585
-
项目类别:
-
资助金额:$9.02万
-
财政年份:2015
-
负责人:KEVIN M. SHANNON
-
依托单位:
(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
-
批准号:8895286
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2013
-
负责人:KEVIN M. SHANNON
-
依托单位:
(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
-
批准号:9112921
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2013
-
负责人:KEVIN M. SHANNON
-
依托单位:
(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
-
批准号:8590462
-
项目类别:
-
资助金额:$32.59万
-
财政年份:2013
-
负责人:KEVIN M. SHANNON
-
依托单位:
(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
-
批准号:8735906
-
项目类别:
-
资助金额:$31.81万
-
财政年份:2013
-
负责人:KEVIN M. SHANNON
-
依托单位:
ID OF MOLECULES THAT SUBSTITUTE FOR ACTIVE NOTCH1 IN T LINEAGE LEUKEMOGENESIS
-
批准号:8363842
-
项目类别:
-
资助金额:$0.23万
-
财政年份:2011
-
负责人:KEVIN M. SHANNON
-
依托单位:
Myeloid Tumor Suppressor Gene Discovery from Chromosome Band 7q22
-
批准号:8319537
-
项目类别:
-
资助金额:$43.4万
-
财政年份:2011
-
负责人:KEVIN M. SHANNON
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: